This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Water deprivation and desmopressin test

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Urine and plasma osmolalities are observed in response to fluid deprivation and subsequent administration of desmopressin. Careful supervision is essential and the test should be discontinued if 5% of initial body weight is lost; 3% in children.

Free access to fluid is permitted until the start of the test. During the test, dry food is permitted but not fluid; at timed hourly intervals for up to 8 hours the following are measured:

  • weight
  • urine volume and osmolality
  • serum osmolality

2 mcg IM desmopressin is administered at the end of 8 hours. Urine is collected for a further 16 hours during which time fluid intake is allowed but restricted to a maximum of 1.5 times the urine volume voided during the dehydration period. Blood is collected at the end of the 16 hours and plasma osmolality measured.

Results may be interpreted as:

  • urine osmolality less than 300 mosmol/kg after fluid deprivation and greater than 800 mosmol/kg after desmopressin suggests cranial diabetes insipidus
  • urine osmolality less than 300 mosmol/kg after fluid deprivation and less than 300 mosmol/kg after desmopressin suggests nephrogenic diabetes insipidus
  • urine osmolarity greater than 800 mosmol/kg after fluid deprivation and greater than 800 mosmol/kg after desmopressin suggests primary polydipsia

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.